{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:26:15Z","timestamp":1788272775411,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.psychres.2025.116559","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:23:08Z","timestamp":1747941788000},"page":"116559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov"],"prefix":"10.1016","volume":"350","author":[{"given":"Damian","family":"Swieczkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4061-775X","authenticated-orcid":false,"given":"Aleksander","family":"Kwa\u015bny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0777-5741","authenticated-orcid":false,"given":"Krzysztof","family":"Sadko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2140-9732","authenticated-orcid":false,"given":"Michal","family":"Pruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Gaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-5455","authenticated-orcid":false,"given":"Lukasz","family":"Szarpak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-8454","authenticated-orcid":false,"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.psychres.2025.116559_bib0001","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","article-title":"The role of dissociation in ketamine\u2019s antidepressant effects","volume":"11","author":"Ballard","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.psychres.2025.116559_bib0002","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10601331003777444","article-title":"Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol","volume":"27","author":"Bang","year":"2010","journal-title":"Clin. Res. Regul. Aff."},{"issue":"1","key":"10.1016\/j.psychres.2025.116559_bib0003","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1192\/j.eurpsy.2023.2479","article-title":"The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers","volume":"67","author":"Butlen-Ducuing","year":"2023","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116559_bib0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.psychres.2025.116559_bib0005","article-title":"A real-world pharmacovigilance study of esketamine nasal spray","volume":"103","author":"Chen","year":"2024","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.psychres.2025.116559_bib0007","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1037\/pst0000169","article-title":"A meta-analysis of the association between patients' early treatment outcome expectation and their posttreatment outcomes","volume":"55","author":"Constantino","year":"2018","journal-title":"Psychotherapy"},{"key":"10.1016\/j.psychres.2025.116559_bib0008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/15563650.2024.2380773","article-title":"Can mind-altering prescription medicines be safe? Lessons from ketamine and esketamine","volume":"62","author":"Dart","year":"2024","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.psychres.2025.116559_bib0009","series-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment of Depression (EMA\/CHMP\/185423\/2010 Rev. 3)","year":"2025"},{"issue":"1","key":"10.1016\/j.psychres.2025.116559_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41386-023-01600-9","article-title":"How should we design future mechanistic and\/or efficacy clinical trials?","volume":"49","author":"Fava","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2025.116559_bib0011","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis","volume":"182","author":"Fountoulakis","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116559_bib0012","series-title":"Psychedelic Drugs: Considerations for Clinical Investigations (Draft Guidance)","year":"2023"},{"issue":"14","key":"10.1016\/j.psychres.2025.116559_bib0013","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1017\/S0033291722003191","article-title":"Is good science leading the way in the therapeutic use of psychedelic drugs?","volume":"52","author":"Hall","year":"2022","journal-title":"Psychol. Med."},{"issue":"8","key":"10.1016\/j.psychres.2025.116559_bib0014","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/s41380-022-01587-7","article-title":"Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic?","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2025.116559_bib0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00406-023-01570-5","article-title":"Arketamine for cognitive impairment in psychiatric disorders","volume":"273","author":"Hashimoto","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.psychres.2025.116559_bib0016","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1192\/bjp.2020.89","article-title":"Are we repeating mistakes of the past? A review of the evidence for esketamine","volume":"219","author":"Horowitz","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116559_bib0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jad.2024.04.062","article-title":"Long-term follow-up of participants in ketamine clinical trials for mood disorders","volume":"357","author":"Hurst","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2025.116559_bib0018","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jad.2024.07.128","article-title":"A replication study using the World Health Organization pharmacovigilance database (VigiBase\u00ae) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists","volume":"363","author":"Kwan","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2025.116559_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1223145","article-title":"Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression","volume":"17","author":"Lullau","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.psychres.2025.116559_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1346697","article-title":"Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis","volume":"15","author":"Matsingos","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2025.116559_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.4312","article-title":"Modifying informed consent to help address functional unmasking in psychedelic clinical trials","volume":"82","author":"Matvey","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2025.116559_bib0022","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2025.116559_bib38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.psychres.2025.116559_bib0024","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","article-title":"International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators","volume":"27","author":"Price","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116559_bib0025","article-title":"No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC","year":"2014","journal-title":"Off. J. Eur. Union"},{"issue":"4","key":"10.1016\/j.psychres.2025.116559_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae017","article-title":"Acute dissociation and Ketamine\u2019s antidepressant and anti-suicidal ideation effects in a midazolam-controlled trial","volume":"27","author":"Sajid","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116559_bib0028","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/npp.2014.261","article-title":"Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?","volume":"40","author":"Sanacora","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2025.116559_bib0029","article-title":"Understanding the Hawthorne effect","volume":"351","author":"Sedgwick","year":"2015","journal-title":"Br. Med. J."},{"issue":"12","key":"10.1016\/j.psychres.2025.116559_bib0030","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.3390\/ijms25126804","article-title":"(R)-(-)-Ketamine: the promise of a novel treatment for psychiatric and neurological disorders","volume":"25","author":"Shafique","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.psychres.2025.116559_bib0031","first-page":"512","article-title":"Expectancy effects in psychedelic trials. Biological psychiatry","volume":"9","author":"Szigeti","year":"2024","journal-title":"Cognit. Neurosci. Neuroimag."},{"key":"10.1016\/j.psychres.2025.116559_bib39","article-title":"Spravato (esketamine) [Drug approval information]","year":"2019","journal-title":"Drugs@FDA"},{"key":"10.1016\/j.psychres.2025.116559_bib0032","first-page":"5","article-title":"The nocebo effect as a source of bias in the assessment of treatment effects","volume":"8","author":"Wartolowska","year":"2019","journal-title":"F1000Res."},{"issue":"1","key":"10.1016\/j.psychres.2025.116559_bib0033","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116559_bib0034","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jad.2024.08.222","article-title":"Effects of arketamine on depression-like behaviors and demyelination in mice exposed to chronic restrain stress: a role of transforming growth factor-\u03b21","volume":"367","author":"Xu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.psychres.2025.116559_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116559_bib0036","first-page":"218","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2025.116559_bib0037","article-title":"Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023","author":"Zhao","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:57:12Z","timestamp":1778565432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"alternative-id":["S0165178125002070"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116559","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116559"}}